STATEMENT: Sanofi restructures R&D in new Boston hub

This morning, FierceBiotech received a statement from a Sanofi spokesperson about their R&D announcements today. It reads:

Sanofi is the leading life sciences company in the Boston area, one of the most important biotechnology and research centers in the world.

The company has continued to grow through external partnerships and business development, most recently through the acquisition of Genzyme Corporation last year.

As part of the integration process between Sanofi and Genzyme, R&D activities were reviewed and assessed. On January 31, 2012, the results of the review of U.S. R&D Genzyme activities were announced, including synergies that unfortunately make some positions redundant.

All US R&D Genzyme employees impacted by the integration received notice regarding whether their position would be relocated or eliminated.

The employees who are leaving Genzyme have made important contributions to the company, and we appreciate their dedication and service to patients. Affected employees will be offered severance packages and outplacement assistance services to help them transition to new employment.

Sanofi is committed to Massachusetts and the Boston area. We anticipate maintaining a stable staff level in the area. The recently announced Boston R&D Hub is a key example of Sanofi's long-term commitment to Massachusetts. As some positions are eliminated, we are investing and hiring in other areas, such as manufacturing and multiple sclerosis.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.